Literature DB >> 15186934

The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania.

Paul E Simonsen1, Stephen M Magesa, Samuel K Dunyo, Mwele N Malecela-Lazaro, Edwin Michael.   

Abstract

Examination of 1829 children from 6 primary schools in coastal Tanzania revealed overall Wuchereria bancrofti microfilaria (mf) and circulating filarial antigen (CFA) prevalences of 17.3% and 43.7%, respectively. A randomized double-blind field trial with a single dose of ivermectin (150-200 microg/kg body weight) alone or in combination with albendazole (400 mg) was subsequently carried out among these children. Both treatment regimens resulted in a considerable decrease in mean mf intensities, with overall reductions being slightly but statistically significantly higher for the combination than for ivermectin alone. The difference in effect between the two treatment regimens was most pronounced at 6 months, whereas it was minor at 12 months after treatment. The relative effect of treatment on mean CFA units was less pronounced than on mf. For both treatment regimens, reductions in CFA intensity appeared to be higher in children who were both CFA and mf positive before treatment, which may suggest that treatment mainly affected the survival and/or production of mf, rather than the survival of adult worms. New cases of infection appeared after treatment with both regimens among the pre-treatment mf and CFA negative children. Adverse reactions were few and mild in both groups, and mainly reported from pre-treatment mf and CFA positive children. The alarmingly high prevalence of W. bancrofti infection in primary school children highlights the importance of also determining the reversibility of already acquired early lesions, and the development of new measures and strategies to specifically protect children from later developing clinical disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15186934     DOI: 10.1016/j.trstmh.2003.12.005

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  16 in total

1.  Cost-effective antigen testing for delimitation, monitoring and evaluation in bancroftian filariasis.

Authors:  L K Das; S P Pani; P Vanamail; G Vijayalakshmi; L J Debritto
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-01-31       Impact factor: 3.267

2.  Lymphatic filariasis control in Tanzania: effect of repeated mass drug administration with ivermectin and albendazole on infection and transmission.

Authors:  Paul E Simonsen; Erling M Pedersen; Rwehumbiza T Rwegoshora; Mwelecele N Malecela; Yahya A Derua; Stephen M Magesa
Journal:  PLoS Negl Trop Dis       Date:  2010-06-01

3.  Impact of basic lymphedema management and antifilarial treatment on acute dermatolymphangioadenitis episodes and filarial antigenaemia.

Authors:  Ha El-Nahas; Am El-Shazly; M Abulhassan; Na Nabih; N Mousa
Journal:  J Glob Infect Dis       Date:  2011-07

4.  The impact of mass drug administration and long-lasting insecticidal net distribution on Wuchereria bancrofti infection in humans and mosquitoes: an observational study in northern Uganda.

Authors:  Ruth A Ashton; Daniel J Kyabayinze; Tom Opio; Anna Auma; Tansy Edwards; Gabriel Matwale; Ambrose Onapa; Simon Brooker; Jan H Kolaczinski
Journal:  Parasit Vectors       Date:  2011-07-15       Impact factor: 3.876

5.  Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis.

Authors:  Cara L Macfarlane; Shyam S Budhathoki; Samuel Johnson; Marty Richardson; Paul Garner
Journal:  Cochrane Database Syst Rev       Date:  2019-01-08

6.  Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves pathology in lymphatic filariasis.

Authors:  Alexander Yaw Debrah; Sabine Mand; Sabine Specht; Yeboah Marfo-Debrekyei; Linda Batsa; Kenneth Pfarr; John Larbi; Bernard Lawson; Mark Taylor; Ohene Adjei; Achim Hoerauf
Journal:  PLoS Pathog       Date:  2006-09       Impact factor: 6.823

7.  The impact of residual infections on Anopheles-transmitted Wuchereria bancrofti after multiple rounds of mass drug administration.

Authors:  Dziedzom K de Souza; Rashid Ansumana; Santigie Sessay; Abu Conteh; Benjamin Koudou; Maria P Rebollo; Joseph Koroma; Daniel A Boakye; Moses J Bockarie
Journal:  Parasit Vectors       Date:  2015-09-24       Impact factor: 3.876

8.  Lymphatic filariasis control in Tanzania: effect of six rounds of mass drug administration with ivermectin and albendazole on infection and transmission.

Authors:  Paul E Simonsen; Yahya A Derua; William N Kisinza; Stephen M Magesa; Mwele N Malecela; Erling M Pedersen
Journal:  BMC Infect Dis       Date:  2013-07-21       Impact factor: 3.090

9.  Prevalence of Lymphatic Filariasis and Treatment Effectiveness of Albendazole/ Ivermectin in Individuals with HIV Co-infection in Southwest-Tanzania.

Authors:  Inge Kroidl; Elmar Saathof; Lucas Maganga; Petra Clowes; Leonard Maboko; Achim Hoerauf; Williams H Makunde; Antelmo Haule; Prisca Mviombo; Bettina Pitter; Neema Mgeni; Joseph Mabuye; Dickens Kowuor; Upendo Mwingira; Mwelecele N Malecela; Thomas Löscher; Michael Hoelscher
Journal:  PLoS Negl Trop Dis       Date:  2016-04-12

10.  Community-based trial of annual versus biannual single-dose ivermectin plus albendazole against Wuchereria bancrofti infection in human and mosquito populations: study protocol for a cluster randomised controlled trial.

Authors:  Dziedzom K de Souza; Collins S Ahorlu; Susan Adu-Amankwah; Joseph Otchere; Sedzro K Mensah; Irene A Larbi; George E Mensah; Nana-Kwadwo Biritwum; Daniel A Boakye
Journal:  Trials       Date:  2017-10-02       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.